TY - JOUR
T1 - Genetic risk classification for adults with AML receiving less-intensive therapies
T2 - the 2024 ELN recommendations
AU - Döhner, Hartmut
AU - DiNardo, Courtney D.
AU - Appelbaum, Frederick R.
AU - Craddock, Charles
AU - Dombret, Hervé
AU - Ebert, Benjamin L.
AU - Fenaux, Pierre
AU - Godley, Lucy A.
AU - Hasserjian, Robert P.
AU - Larson, Richard A.
AU - Levine, Ross L.
AU - Miyazaki, Yasushi
AU - Niederwieser, Dietger
AU - Ossenkoppele, Gert
AU - Röllig, Christoph
AU - Sierra, Jorge
AU - Stein, Eytan M.
AU - Tallman, Martin S.
AU - Tien, Hwei Fang
AU - Wang, Jianxiang
AU - Wierzbowska, Agnieszka
AU - Wei, Andrew H.
AU - Löwenberg, Bob
N1 - Publisher Copyright:
© 2024 American Society of Hematology
PY - 2024/8/12
Y1 - 2024/8/12
N2 - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
AB - The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
UR - http://www.scopus.com/inward/record.url?scp=85203490901&partnerID=8YFLogxK
U2 - 10.1182/blood.2024025409
DO - 10.1182/blood.2024025409
M3 - Comment/Letter to the editor
C2 - 39133932
AN - SCOPUS:85203490901
SN - 0006-4971
VL - 144
SP - 2169
EP - 2173
JO - Blood
JF - Blood
IS - 21
ER -